Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug;Toxicidad pleuropulmonar precoz asociada al tratamiento con cabergolina, un fármaco antiparkinsoniano

Archivos de Bronconeumologia

Volumn 43, Issue 9, 2007, Pages 519-522

  Villavicencio, Christian ^a   Ramírez Sarmiento, Alba ^b   Gayete, Ángel ^a   Grau, Santiago ^a   Orozco Levi, Mauricio ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Cabergoline; Pleural effusion; Pulmonary toxicity

Indexed keywords

ANTIPARKINSON AGENT; CABERGOLINE; CARBON MONOXIDE; SOGILEN; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ARTICLE; CLINICAL ASSESSMENT; COUGHING; DYSPNEA; EARLY DIAGNOSIS; EDEMA; FOLLOW UP; HUMAN; LEG DISEASE; LUNG CAPACITY; LUNG DISEASE; LUNG FUNCTION; OUTCOME ASSESSMENT; PERICARDIAL DISEASE; PLEURA EFFUSION; RATING SCALE; RESPIRATORY FUNCTION; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 36048947333     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13109474     Document Type: Article

References (11)

1. Fishman AF. Pulmonary diseases and disorders. Vol. 1. 2nd ed. New York: McGraw Hill; 1988. p. 798
2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
3. Wickersham RM, Novak KK, Schweain SL. Drug facts and comparisons. St. Louis: Facts and Comparisons, Inc.; 2006.
4. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2003;2:23-32.
5. Gottwald MD, Bainbridge JL, Dowling GA, Aminoff MJ, Alldredge BK. New pharmacotherapy for Parkinson's disease. Ann Pharmacother. 1997;31:1205-17.
6. Guptha S, Promnitz A. Pleural effusion and thickening due to cabergoline use in a patient with Parkinson's disease. Eur J Intern Med. 2005;16:129-31.
7. Catálogo de Especialidades Farmacéuticas. Consejo Plus. Madrid: Consejo General de Colegios Oficiales Farmacéuticos; 2006. Tomo I. p. 2214-5.
8. Geminiani G, Fetoni V, Genitrini S, Giovannini P, Tamma F, Caraceni T. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord. 1996;11:495-500.
9. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J. 1992;5:263-5.
10. Micromedex® Healthcare Series [Internet database]. Greenwood Vil[lage, Colorado: Thomson Micromedex.
11. Hofmann C, Penner U, Dorow R, Pertz HH, Jahnichen S, Horowski R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol. 2006;29:80-6.